Paper Details

  1. Home
  2. Paper Details

Treatment of isoniazid-resistant tuberculosis with first-line drugs: a systematic review and meta-analysis.

Author: BenedettiAndrea, GegiaMedea, MenziesDick, WintersNicholas, van SoolingenDick

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Meta-AnalysisA statistical technique that integrates the results of multiple studies to draw more general conclusions about a particular issue.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.
Systematic ReviewA review that systematically collects, evaluates, and integrates relevant research to answer a specific research question.

Overview

This updated systematic review examines treatment outcomes associated with the use of first-line drugs in patients with tuberculosis resistant to isoniazid but not rifampicin. The study investigates the potential limitations of current treatment regimens for this type of drug-resistant TB.
Paper Details　
Original Abstract of the Article :
The results of some reports have suggested that treatment of isoniazid-resistant tuberculosis with the recommended regimens of first-line drugs might be suboptimal. We updated a previous systematic review of treatment outcomes associated with use of first-line drugs in patients with tuberculosis res...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1016/S1473-3099(16)30407-8

データ提供：米国国立医学図書館（NLM）

Treating Isoniazid-Resistant Tuberculosis with First-Line Drugs: A Systematic Review and Meta-Analysis

This systematic review and meta-analysis examines the effectiveness of first-line drug regimens in treating isoniazid-resistant tuberculosis, a challenging form of the disease. The authors analyzed existing research to assess the treatment outcomes associated with the use of first-line drugs in patients with isoniazid resistance. The review found that treatment of isoniazid-resistant tuberculosis with recommended first-line drug regimens may be suboptimal. Further research is needed to optimize treatment strategies for this specific form of tuberculosis.

Addressing the Challenge of Drug-Resistant Tuberculosis

The review highlights the ongoing need for improved treatment strategies for drug-resistant tuberculosis. The findings emphasize the importance of ongoing research to develop more effective treatment regimens and prevent the spread of drug-resistant strains.

Combating the Spread of Drug-Resistant Tuberculosis

The review highlights the significant challenge posed by drug-resistant tuberculosis. It underscores the importance of adhering to prescribed treatment regimens, preventing the spread of infection, and developing new and effective treatment strategies to address this growing public health threat.

Dr.Camel's Conclusion

Just like a camel facing a harsh desert environment, researchers are battling the persistent threat of drug-resistant tuberculosis. This review reveals that existing treatment strategies for isoniazid-resistant tuberculosis may not be optimal. It underscores the urgent need for further research and development to find more effective therapies and combat this tenacious foe.

Date :
  1. Date Completed 2017-06-12
  2. Date Revised 2022-04-10
Further Info :

Pubmed ID

27865891

DOI: Digital Object Identifier

10.1016/S1473-3099(16)30407-8

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.